Ya-Chi Chen
Chief Scientific Officer OBI Pharma
Seminars
Monday 12th October 2026
Best of Both Worlds? Spotlighting Discovery of Bispecific, Dual Payload ADC OBI-221: 2 + 2 = Innovation
- Exploring rationale and design of OBI-221, a dual payload bispecific ADC targeting cMET/HER3
- Outlining lessons learned from pursuing a two hit, two target approach to guide future ADC innovation opportunities
- Evaluating initial characterization of OBI-221, contextualized with early clinical performance of TROP2 ADC leveraging same design principles
